A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY (ZEST)
Details
Age
Adult
Type of Study
Treatment
Locations
Highlands Ranch Hospital
Lone Tree Medical Center
University of Colorado Hospital
Principal Investigator
Marie Wood, MD
Study ID
Protocol Number: 21-3616
More information available at ClinicalTrials.gov: NCT04915755
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers